74420-18-1

Basic information

• Product Name: 7-Hydroxy-1H-pyrrolo<2,3-b>pyridinium m-chlorobenzoate
• Synonyms: 7-Hydroxy-1H-pyrrolo<2,3-b>pyridinium m-chlorobenzoate
• CAS NO: 74420-18-1
• Molecular Weight: 290.706
• Mol File: 74420-18-1.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: 7-Hydroxy-1H-pyrrolo<2,3-b>pyridinium m-chlorobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Hydroxy-1H-pyrrolo<2,3-b>pyridinium m-chlorobenzoate(74420-18-1)
• EPA Substance Registry System: 7-Hydroxy-1H-pyrrolo<2,3-b>pyridinium m-chlorobenzoate(74420-18-1)

Safety Data

• Hazardous Substances Data: 74420-18-1(Hazardous Substances Data)

Upstream product

• 271-63-6 7-Azaindole 
• 937-14-4 3-chloro-benzenecarboperoxoic acid 

Downstream Products

• 74420-07-8 3-nitro-1H-pyrrolo<2,3-b>pyridine 7-oxide 
• 55052-24-9 1H-Pyrrolo[2,3-b]pyridine-7-oxide 
• 55052-28-3 4-chloro-7-azaindole 
• 1314863-20-1 N-(1-(4-nitrophenyl)-1H-pyrrolo[3,2-c]pyridin-4-yl)benzamide 
• 1314863-22-3 N-(1-(4-aminophenyl)-1H-pyrrolo[3,2-c]pyridin-4-yl)benzamide 
• 1314863-24-5 N-(1-(4-[3-(2,3-dichlorophenyl)urea]phenyl)-1H-pyrrolo[3,2-c]pyridin-4-yl)benzamide 
• 1314863-25-6 1-(4-(4-benzamido-1H-pyrrolo[3,2-c]pyridin-1-yl)phenyl)-3-(3,4-dichlorophenyl)urea 
• 1314863-26-7 1-(4-(4-benzamido-1H-pyrrolo[3,2-c]pyridin-1-yl)phenyl)-3-(3-trifluoromethylphenyl)urea 
• 1314863-27-8 1-(4-(4-benzamido-1H-pyrrolo[3,2-c]pyridin-1-yl)phenyl)-3-(4-chloro-3-trifluoromethylphenyl)urea 
• 1314863-28-9 1-(3,5-bis(trifluoromethyl)phenyl)-3-(4-(4-benzamido-1H-pyrrolo[3,2-c]pyridin-1-yl)phenyl)urea 
• 1314863-30-3 1-(4-(4-benzamido-1H-pyrrolo[3,2-c]pyridin-1-yl)phenyl)-3-(4-((4-ethylpiperazin-1-yl)methyl)-3-trifluoromethylphenyl)urea 
• 1314863-33-6 N-[4-(4-benzamido-1H-pyrrolo[3,2-c]pyridin-1-yl)phenyl]-3-trifluoromethylbenzamide 
• 1314863-34-7 N-[4-(4-benzamido-1H-pyrrolo[3,2-c]pyridin-1-yl)phenyl]-4-chloro-3-(trifluoromethyl)benzamide 
• 1314863-35-8 N-[4-(4-benzamido-1H-pyrrolo[3,2-c]pyridin-1-yl)phenyl]-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzamide 

Relevant articles and documents

Synthesis of 4-Amino-1H-pyrrolopyridine (1,7-Dideazaadenine) and 1H-Pyrrolopyridin-4-ol (1,7-Dideazahypoxanthine)

4-Amino-1H-pyrrolopyridine (1,7-dideazaadenine) (5) has been synthesized by the iron and acetic acid reduction of 4-nitro-1H-pyrrolopyridine 7-oxide (13), obtained by nitration of 1H-pyrrolopyridine-3-carboxamide 7-oxide (17).Other nitration reactions in the 1H-pyrrolopyridine 7-oxide series are disclosed.The preparation of 1H-pyrrolopyridin-4-ol (1,7-dideazahypoxanthine) (6) began with the hydrolysis of ethyl 1-benzyl-3-cyano-4-oxo-4,7-dihydro-1H-pyrrolopyridine-5-carboxylate (21) to the 3,5-dicarboxylic acid derivative of 1-benzyl-4-oxo-4,7-dihydro-1H-pyrrolopyridine (22).Decarboxylation of 22 with subsequent debenzylation formed 6.

Cell-based biological evaluation of a new bisamide FMS kinase inhibitor possessing pyrrolo[3,2-c]pyridine scaffold

A bisamide compound 1 possessing the pyrrolo[3,2-c]pyridine nucleus was synthesized and biologically evaluated. It was tested for kinase inhibitory activity over a panel of 47 kinases, and its selectivity toward the FMS kinase was accidentally discovered. Compound 1 was tested over a panel of seven ovarian, two prostate, and six breast cancer cell lines at a single dose concentration of 10μM and showed high activity. It was further tested in a 5-dose mode to determine its IC50 and total growth inhibition (TGI) values over the 15 cell lines. Compound 1 showed high potency on the submicromolar scale and good efficacy. The cytotoxic effect of compound 1 over peritoneal macrophages was also investigated. Compound 1 demonstrated higher selectivity against different cancer cell lines compared with HS-27 fibroblasts.

Design and synthesis of an anticancer diarylurea derivative with multiple-kinase inhibitory effect

A diarylurea compound 1 possessing pyrrolo[3,2-c]pyridine nucleus was designed and synthesized with structure similarity to Sorafenib. Compound 1 was tested over 60-cancer cell line panel at a single dose concentration of 10 μM and showed high activity. It was further tested in a five-dose mode to determine its IC50, TGI, and LC50 values over the 60 cell lines. Compound 1 showed high potency and good efficacy, and was accordingly tested at a single dose concentration of 10 μM over a panel of 40 kinases. At this concentration, it completely inhibited the enzymatic activities of a number of oncogenic kinases, including ABL, ALK, c-RAF, FLT3, KDR, and TrkB. The target compound was subsequently tested over these 6 kinases in 10-dose testing mode in order to determine its IC50 values. Copyright